研報掘金丨開源證券:首予衆生藥業“買入”評級,看好未來中藥板塊穩健增長
開源證券研報指出,衆生藥業夯實中藥根基,創新引領發展。是一家集藥品研發、生產和銷售爲一體的中國醫藥工業百強企業,立足於心腦血管、呼吸、眼科、消化等治療領域,主要產品有複方血栓通系列、腦栓通膠囊、衆生丸等。同時,公司已建立起“中藥爲基,創新引領,聚焦特色”的發展戰略,子公司衆生睿創佈局多領域創新管線,伴隨產品陸續成功上市步入收穫期,公司整體產品集羣梯隊日益豐富,核心競爭力不斷提升。該行看好公司未來中藥板塊穩健增長,創新藥管線大力推進帶來的潛在成長性,首次覆蓋給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.